Hemostemix Inc. (CVE:HEM – Get Free Report) shares traded up 17.9% during mid-day trading on Thursday . The stock traded as high as C$0.33 and last traded at C$0.33. 1,140,716 shares traded hands during mid-day trading, an increase of 72% from the average session volume of 663,769 shares. The stock had previously closed at C$0.28.
Hemostemix Stock Up 25.0 %
The stock has a 50-day moving average price of C$0.12 and a 200 day moving average price of C$0.09. The firm has a market capitalization of C$30.49 million, a price-to-earnings ratio of -17.50 and a beta of 0.20.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- The Risks of Owning Bonds
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Airline Stocks – Top Airline Stocks to Buy Now
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
